Kite, a Gilead Company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel), a CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory primary central nervous system lymphoma (PCNSL).
Addressing an Unmet Need
Primary central nervous system lymphoma is a rare and aggressive form of non-Hodgkin lymphoma with limited treatment options and poor prognosis. This approval represents an important advancement in expanding access to innovative therapies for patients in need.
Clinical Evidence
The approval is based on clinical trial data demonstrating high response rates and durable remissions in patients treated with Yescarta. The safety profile observed was consistent with previously reported data.
"This approval reflects our continued commitment to developing innovative therapies that address unmet medical needs and improve outcomes for patients living with cancer."
About Yescarta®
Yescarta is a CAR T-cell therapy that involves collecting a patient's T cells and genetically modifying them to target and destroy cancer cells. These engineered cells are then infused back into the patient, offering a personalized approach to cancer treatment.
Commitment to Innovation
Kite remains committed to advancing cell therapy and delivering transformative treatments to patients with difficult-to-treat cancers. This approval expands the use of Yescarta to patients with limited treatment options and represents a significant advancement in addressing this rare and aggressive form of lymphoma.